Inclusion Criteria:

- Subjects diagnosed with advanced solid malignancies who are refractory to standard
therapies or for which no standard therapy exists.

- Subjects who have overall good overall general condition.

- Subjects who agree to hospitalisation from starting olaparib to multiple dose period
at day 15.

- Evidence of non-childbearing status for women of childbearing potential, or
postmenopausal status.

- Subjects who have at least one lesion (measurable and/or non-measurable) that can be
accurately assessed by CT/MRI at baseline and follow up visits

Exclusion Criteria:

- Subjects who received any previous treatment with a PARP (poly adenosine
diphosphate-ribose polymerase) inhibitor, including olaparib.

- Subjects receiving inhibitors of CYP3A4 (cytochrome P450 3A4).

- Subjects with symptomatic uncontrolled brain metastases.

- Subjects with myelodysplastic syndrome/acute myeloid leukaemia.

- Subjects with a known hypersensitivity to olaparib or any of the excipients of the
product.